retatrutide triple agonist glp-1 gip glucagon phase 2 results Retatrutide: The Next Generation of Weight Loss Medication? Retatrutide Results: 28.3% Weight Loss

15,16 Figure 2

Those on semaglutide 2.4 mg weekly had a 20% lower relative risk of major cardiovascular events, including heart attack and stroke, over a median follow-up of nearly 40 months

Conclusion Can you take an antihistamine with Mounjaro

The 25-34 audience stands out as the most receptive age group: over 54% would actively seek a prescription nearly 56% find pills more appealing than injections a striking 87.38% of current injectable users would consider switching to tablets This suggests oral GLP-1s may particularly resonate with younger working-age adults who value convenience, discretion, and familiarity with daily medication formats